EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

Category Primary study
JournalBLOOD
Year 2023
This article has no abstract
Epistemonikos ID: bd9aecd3028b9bcee5db2f3b41201e9c9e665e67
First added on: Apr 29, 2024